Sector Watch: Nifty Pharma index slips up to 3% dragged by Sun Pharma

Nifty Pharma index emerged as the top sectoral loser on NSE in the morning deals on Monday, weighed down by the shares of Sun Pharmaceutical Industries, which slumped as much as 10 per cent.

Pharma Stocks, Sun Pharma, Cadila, Cipla
Pharma Stocks, Sun Pharma, Cadila, Cipla
SI Reporter New Delhi
Last Updated : Dec 03 2018 | 10:30 AM IST
Nifty Pharma index emerged as the top sectoral loser on NSE in the morning deals on Monday, weighed down by the shares of Sun Pharmaceutical Industries, which slumped as much as 10 per cent. The index slipped up to 3 per cent in the early morning trade. At 10:20 am, the index was trading 1.61 per cent lower at 9,129, with six constituents in the red and four in the green.

Sun Pharma came under heavy pressure amid reports news reports markets regulator, the Securities and Exchange Board of India (Sebi) is likely to reopen an insider trading case against the drug major as well as probe alleged lapses by some of its promoters and other entities in raising funds overseas.

“The market regulator was in receipt of a 150-page letter in which the whistle-blower accused the company of committing corporate governance and tax-related lapses, besides other securities market-related violations,” the Business Standard reported quoting regulatory sources.

Last week, the stock touched a six-month low after a foreign brokerage raised concerns about corporate governance practices at the drug major. 

At 10:20 am, shares of Sun Pharma were trading 7.23 per cent lower at Rs 457, Biocon was trading at 619.80, down 0.73 per cent while shares of Cipla were trading around 0.27 per cent lower at 539.40 on NSE, as compared to a 0.34 per cent rise in the Nifty 50 index.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Next Story